Brand Name

Daunorubicin

View Brand Information
FDA approval date: January 02, 2018
Classification: Anthracycline Topoisomerase Inhibitor
Form: Injection

What is Daunorubicin?

Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia of adults and for remission induction in acute lymphocytic leukemia of children and adults.

Approved To Treat

Top Global Experts

View All
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Who is this study for: Child to young adult patients with Acute Myeloid Leukemia
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Other, Drug
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Dexrazoxane, Etoposide, Gemtuzumab, Gilteritinib, Liposomal Daunorubicin, Liposomal Cytarabine, Methotrexate, Mitoxantrone, Hydrocortisone
Study Phase: Phase 3

Summary: This phase III trial compares standard chemotherapy to therapy with liposome-encapsulated daunorubicin-cytarabine (CPX-351) and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing t...

A Phase III, Multicentre, Open-Label, Randomised Study Evaluating the Efficacy and Safety of R-mini-CHOP x2 Followed by AZD0486 Versus R-mini-CHOP x6 in Elderly or Unfit Participants With Newly Diagnosed Large B-cell Lymphoma (SOUNDTRACK-D2)
A Phase III, Multicentre, Open-Label, Randomised Study Evaluating the Efficacy and Safety of R-mini-CHOP x2 Followed by AZD0486 Versus R-mini-CHOP x6 in Elderly or Unfit Participants With Newly Diagnosed Large B-cell Lymphoma (SOUNDTRACK-D2)
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Drug
Study Phase: Phase 3

Summary: The purpose of this study is to measure the efficacy and safety of R-mini-CHOP × 2 followed by AZD0486 compared with R-mini-CHOP × 6 in elderly or unfit participants newly diagnosed with LBCL.

A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Dedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Dedifferentiated Liposarcoma (DDLPS), Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
Enrollment Status: Recruiting
Publish Date: June 18, 2026
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 3

Summary: This phase III trial compares the effect of immunotherapy (pembrolizumab) plus chemotherapy (doxorubicin) to chemotherapy (doxorubicin) alone in treating patients with dedifferentiated liposarcoma (DDLPS), undifferentiated pleomorphic sarcoma (UPS) or a related poorly differentiated sarcoma that has spread from where it first started (primary site) to other places in the body (metastatic) or that ...

View All Clinical Trials

Related Latest Advances

Targeted therapy of highly aggressive thyroid papillary carcinoma by AS1411-guided nanomaterials.
Targeted therapy of highly aggressive thyroid papillary carcinoma by AS1411-guided nanomaterials.
Journal: Nanomedicine (London, England)
Published: June 23, 2026
Wax-printing-free fabrication of paper-supported 3D cancer cell culture.
Wax-printing-free fabrication of paper-supported 3D cancer cell culture.
Journal: Analytical methods : advancing methods and applications
Published: June 23, 2026
NINJ1 Aggravates Doxorubicin-Induced Cardiotoxicity by Suppressing AMPK-Mediated HIF-1α Deubiquitination.
NINJ1 Aggravates Doxorubicin-Induced Cardiotoxicity by Suppressing AMPK-Mediated HIF-1α Deubiquitination.
Journal: Antioxidants & redox signaling
Published: June 23, 2026
View All Latest Advances